(UroToday.com) Though clinical outcomes for advanced germ cell tumors have been significantly improved with the utilization of cisplatin-based chemotherapy regimens, approximately 400 patients a year die from relapsed or refractory germ cell tumors. To further explore the genetic properties of cisplatin refractory or relapsed germ cell tumors, 52 tumors from a single institution were profiled using a hybrid-capture commercial assay and also analyzed for PD-L1 expression using the DAKO 22C3 immunohistochemistry antibody.